Antibiotic stewardship made simple

Prescription meets Precision

Our Why

Our Mission

Elevate antibiotic prescriptions for optimal patient outcomes. We support all medical specialists, preserving future patient health by combatting antimicrobial resistance, ensuring the best results in every case.

We Care

About the patient today

And the patient tomorrow

The Problems

Antimicrobial resistance is a global health and development threat

Antimicrobial Resistance

  • AMR is responsible for 33,000 deaths per year in the EU

  • 670 000 infections due to resistant bacteria

  • AMR has a direct impact on human health

Long Guidelines & SmPCs

  • Clinicians find guidelines too long and complex

  • Comorbidities and allergies complicate treatment decisions

  • Only 10% of physicians read the SmPCs

Economic impact

  • AMR makes infections harder and more expensive to treat

  • €1.5 billion for healthcare costs & productivity losses from AMR

  • 75% of the burden of AMR is due to healthcare-associated infections

The Solution

Software based solution

Our AMIRA software solution helps healthcare practitioners improve the outcome of antibiotic prescription in hospitals while helping fight antibiotic resistance on a global scale.

AMIRA Meditech also provides valuable insights for antibiotic usage for the hospital management and saves economic resources!

Our Team

Management Team

Natalia Konova MD

Natalia Konova MD

Chief Executive Officer

Teodor Stamenov

Teodor Stamenov

Chief Technology Officer

Science and investigation advisory board

Prof. Dr. Emil Gachev, MD. PhD

Prof. Dr. Emil Gachev, MD. PhD

Advisory board member

Prof. Dr. Dobrin Svinarov, MD. PhD

Prof. Dr. Dobrin Svinarov, MD. PhD

Advisory board member

Prof. Boris Sakakushev, MD, PhD

Prof. Boris Sakakushev, MD, PhD

Advisory board member

Prof. Dr. Mariana Murdjeva

Prof. Dr. Mariana Murdjeva

Advisory board member

Prof. Dr. Tsetsa Doichinova, MD

Prof. Dr. Tsetsa Doichinova, MD

Advisory board member

Assoc. prof. Sergey Iliev, MD, Ph.D

Assoc. prof. Sergey Iliev, MD, Ph.D

Advisory board member

F.A.Q

  • It can mean one of the following things:

    1. Unnecessary use – where an antimicrobial is not indicated and there is no health benefit for the patient (e.g. treatment of an upper respiratory infection caused by a virus or an antibiotic is not recommended)
    2. Inappropriate use – where timing, antimicrobial choice, dose, route, frequency of administration or duration of treatment is incorrect. For example:
      • delayed administration in a critically ill patient,
      • choice of an antibiotic with an unnecessarily broad or too narrow spectrum 
      • drug-bug mismatch
      • iv route when oral can be used
      • dose is too high or too low compared to what is indicated for that patient
      • duration is too long or too short
      • duration is > 24 hours for surgical prophylaxis (except where guidelines endorse longer duration)
      • treatment is not streamlined or changed when microbiological culture data become available
      • prescription of agent for patients with a known allergy to the agent
      • drug-drug interaction

  • The 3 main outcomes are:     

    1. Development of resistant organisms, Clostridium difficile infections
    2. Patient harm such as treatment failure, adverse drug events, and increased mortality
    3. Increased healthcare and societal costs

  • They usually use one of the following mechanisms:

    1. Producing destructive enzymes to neutralise antibiotics
    2. Modifying antimicrobial targets by mutation, so that drugs cannot recognize them
    3. Creating bypasses that allow bacteria to function without the enzymes targeted by antibiotics
    4. Preventing antibiotics from entering by creating a “biofilm” or otherwise reducing permeability
    5. Removing antimicrobial agents by pumping them out (efflux)

  • There are several definitions of AS. Here are a few:

    • “Organisational or healthcare system-wide approach to promoting and monitoring
      judicious use of antimicrobials to preserve their future effectiveness”
    • “The optimal selection, dosage, and duration of antimicrobial treatment that results
      in the best clinical outcome for the treatment or prevention of infection, with
      minimal toxicity to the patient and minimal impact on subsequent resistance”
    • „The right antibiotic for the right patient, at the right time, with the right dose, and
      the right route, causing the least harm to the patient and future patients“ (we like this one the most :) )

  • Several studies have found that implementing Antimicrobial stewardship in a hospital setting will have the following benefits:

    1. Improve patient outcomes - improve infection cure rates, reduce surgical infection rates and reduce morbidity and mortality 
    2. Improve patient safety and minimize unintended consequences of antimicrobials - reduce antimicrobial consumption, without increasing mortality or infection-related readmissions
    3. Reduce resistance rates
    4. Reduce healthcare costs without impacting the quality of care

Partners

An investor in "AMIRA Meditech" LTD is "Innovation Capital Fund" KDA that operates with co-financing by the European Regional Development Fund of the operative program "Innovations and competitiveness" 2014-2020, managed by the Fund of Funds Bulgaria. The investment amounts fifty thousand euro.

Contact Us

Send a message and we will respond to you as soon as possible

Address

Sofia, Bulgaria

Phone Number

+359888561901

Your message has been sent. Thank you!